Tofacitinib Versus Methotrexate in Treating Mucocutaneous and Musculoskeletal Lesions of Systemic Lupus Erythematosus: Real‐World Results From the CSTAR Cohort XXXII
International Journal of Rheumatic Diseases · 2025
DOI: 10.1111/1756-185x.70283 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Rheumatic Diseases, 2025. Verfasst von Man Zhao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical …. Hauptthemen laut MEDLINE: Methotrexate, Lupus Erythematosus, Systemic, Piperidines, Pyrimidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Chinese National Key Technology R&D Program, Ministry of Science and Technology (2021YFC2501300), CAMS Innovation Fund for Medical Sciences (CIFMS) (2021-I2M-1-005, 2022-I2M-1-004, 2023-I2M-2-005), Beijing Municipal Science & Technology Commission (No. Z201100005520022,23, 25-27).
Abstract (Originalsprache)
Objectives
This study aimed to evaluate and compare the efficacy and safety of tofacitinib versus methotrexate in the management of systemic lupus erythematosus (SLE) within a real‐world cohort, with a particular focus on mucocutaneous and musculoskeletal involvement.
Methods
We conducted a retrospective analysis based on the Chinese SLE Treatment and Research Group (CSTAR) cohort. Patients with SLE presenting with active mucocutaneous or musculoskeletal involvement who initiated treatment with tofacitinib or methotrexate were included. The primary endpoint was the proportion of patients achieving resolution of mucocutaneous and musculoskeletal symptoms, as defined by the SLE Disease Activity Index 2000, at 3 months.
Results
A total of 109 patients were included in the study, with 44 assigned to the tofacitinib group and 65 to the methotrexate group. The tofacitinib group exhibited a numerically higher trend in resolution proportion for both mucocutaneous (3 months: 88.0% vs. 69.6%, p = 0.162; 6 months: 83.3% vs. 77.8%, p > 0.999) and musculoskeletal (100.0% vs. 84.6%, p = 0.555; 100.0% vs. 73.7%, p = 0.289) involvement compared with the methotrexate group. However, these differences did not reach statistical significance. Survival analysis revealed that tofacitinib was associated with a faster resolution of mucocutaneous ( p = 0.043) involvement compared to methotrexate within a 6‐month follow‐up period. There was no significant difference in the incidence of adverse events between the two groups (2.3% vs. 3.1%, p > 0.999).
Conclusions
Tofacitinib may demonstrate superior effectiveness over methotrexate in the resolution of mucocutaneous involvement in SLE patients, primarily by achieving remission more rapidly, while maintaining a comparable safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
- National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China.
- State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, China.
- Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.
- Department of Rheumatology, People's Hospital of Zhengzhou, Zhengzhou, China.
- Department of Rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
ORCID-Profile: Man Zhao, Leyao Ma, Xinping Tian
Förderung
- Chinese National Key Technology R&D Program, Ministry of Science and Technology (2021YFC2501300)
- CAMS Innovation Fund for Medical Sciences (CIFMS) (2021-I2M-1-005, 2022-I2M-1-004, 2023-I2M-2-005)
- Beijing Municipal Science & Technology Commission (No. Z201100005520022,23, 25-27)
- Project of Henan Province Medical Science and Technology Research Program (LHGJ20240876)
- National High Level Hospital Clinical Research Funding (2022-PUMCH-B-013, C-002, D-009)
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park
Zitieren
APA
Zhao, M., Ma, L., Duan, X., Huo, Y., Liu, S., Zhao, C., Wang, Q., Tian, X., Chen, Y., & Li, M. (2025). Tofacitinib Versus Methotrexate in Treating Mucocutaneous and Musculoskeletal Lesions of Systemic Lupus Erythematosus: Real‐World Results From the CSTAR Cohort XXXII. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70283
Vancouver
Zhao M, Ma L, Duan X, Huo Y, Liu S, Zhao C, et al. Tofacitinib Versus Methotrexate in Treating Mucocutaneous and Musculoskeletal Lesions of Systemic Lupus Erythematosus: Real‐World Results From the CSTAR Cohort XXXII. International Journal of Rheumatic Diseases. 2025. doi:10.1111/1756-185x.70283
BibTeX
@article{Zhao2025,
author = {Zhao, Man and Ma, Leyao and Duan, Xinwang and Huo, Yuehong and Liu, Shengyun and Zhao, Cheng and Wang, Qian and Tian, Xinping and Chen, Yunzhuan and Li, Mengtao},
title = {Tofacitinib Versus Methotrexate in Treating Mucocutaneous and Musculoskeletal Lesions of Systemic Lupus Erythematosus: Real‐World Results From the CSTAR Cohort XXXII},
journal = {International Journal of Rheumatic Diseases},
year = {2025},
doi = {10.1111/1756-185x.70283}
}
EUVIMED